Lindahl assists when Cyxone signs an asset transfer agreement for a candidate drug in phase 2

Cyxone AB has signed an agreement regarding the right to acquire the clinical pharmaceutical candidate Rabeximod from OxyPharma AB. Cyxone will call an extraordinary general meeting to seek shareholder approval for a directed new share issue to enable the completion of the acquisition and a phase 2b study within rheumatoid arthritis.

Cyxone is a biopharmaceutical company that develops pharmaceuticals within autoimmune diseases.

Lindahl assisted Cyxone through Anders Burén (life science).